<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539590</url>
  </required_header>
  <id_info>
    <org_study_id>001-10</org_study_id>
    <secondary_id>5R44HL091699</secondary_id>
    <nct_id>NCT01539590</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack</brief_title>
  <official_title>A Phase 2 Pilot Study to Evaluate the Safety and Activity of BB3 as an Adjunct to Percutaneous Coronary Intervention (PCI) in Subjects Presenting With Acute ST Segment Elevation Myocardial Infarction (STEMI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angion Biomedica Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Angion Biomedica Corp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effect of BB3 to preserve myocardial (heart) tissue and function
      following myocardial infarction (heart attack).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous coronary intervention (PCI) has become the mainstay for treatment of ST-segment
      elevation myocardial infarction (STEMI). Whereas early recanalization undoubtedly salvages
      myocardial tissue, reperfusion following prolonged ischemia can also exacerbate injury.
      Infarct size needs to be limited, and the conditions favoring adaptive ventricular healing
      and remodeling optimized because in patients with acute myocardial infarction (AMI) who do
      not die of out-of-hospital arrhythmias, long-term prognosis is dependent on the amount of
      myocardium that is lost, and the outcome of ventricular remodeling. Angion Biomedical Corp.
      has identified BB3, a small molecule mimetic of hepatocyte growth factor/scatter factor
      (HGF/SF) whose activity is expected to preserve tissue viability and attenuate dysfunction in
      the setting of organ injury while obviating the logistical difficulties associated with gene
      or protein therapy. HGF/SF is a naturally occurring cell survival factor that holds
      significant therapeutic potential. BB3 has been shown to possess HGF/SF activities, including
      protection against heart injury following myocardial infarction. This study is designed to
      evaluate clinical efficacy of BB3 in patients presenting with acute ST segment elevation
      myocardial infarction (A-STEMI) who undergo PCI.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Reduction in Infarct Size</measure>
    <time_frame>6 month</time_frame>
    <description>Evaluation of reduction in infarct size by MRI between the BB3 and placebo treatment groups at 6 months based on index of myocardial salvage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the Degree of Late Ventricular Remodeling</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of the degree of late ventricular remodeling between the BB3 and placebo treatment groups at 6 months, as measured by increase in LV end-diastolic volume index (LVEDVI) from initial MR image (day 5±1) to late MR image (6 months).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CK-MB and Troponin</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BNP Levels</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Symptoms and Clinical Signs of CHF</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LVEDVI, LVESVI and LV Ejection Fraction (EF) After MI Assessed by Cine MR (SSFP Imaging)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEDVI, LVESVI and LVEF After MI Assessed by 2D and 3D Echocardiography</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Between Initial Semi-quantitative Regional Wall Motion Score (17 Segment Model) by Echocardiography</measure>
    <time_frame>1 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Regional Myocardial Radial, Circumferential and Longitudinal Strain</measure>
    <time_frame>1 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of MACE</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of New Onset CHF Through 6 Months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalizations for CHF Through 6 Months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Complete ST Segment Resolution 60 ± 30 Minutes After Last Angiogram</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AE, SAEs</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of MACCE</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Ventricular Fibrillation or Other Life-threatening Arrhythmia</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline eCrCl</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms and Clinical Signs of CHF</measure>
    <time_frame>6 months</time_frame>
    <description>Symptoms and clinical signs of CHF measured by NYHA classification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>BB3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily intravenous administration of 2 mg/kg BB3 for four (4) days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily intravenous administration for four (4) days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BB3</intervention_name>
    <description>Daily intravenous administration of 2 mg/kg BB3 for four (4) days</description>
    <arm_group_label>BB3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject or legally authorized representative has been informed of the nature of
             the study, agrees to its provisions, and has been provided and signed written informed
             consent, approved by the Institutional Review Board (IRB), prior to performance of any
             study related procedure including screening procedure.

          2. Subject is male or female

          3. Subject is 21 to 80 years of age

          4. Estimated body weight &lt; 120 kg and BMI &lt; 40

          5. Subject is experiencing clinical symptoms consistent with acute myocardial infarction
             (AMI) (e.g., chest pain, arm pain, etc.,) &gt;30 minutes duration and unresponsive to
             nitroglycerin; with ST segment elevation of more than 1 mm in at least two contiguous
             leads of ECG or new or presumed new onset bundle branch block (BBB)

          6. Fulfills clinical center's criteria for primary PCI

          7. PCI will be done within 12 hours of onset of STEMI.

          8. The subject and his/her physician are willing to comply with the requirements of the
             study and the specified follow-up evaluations.

          9. If female, either surgically sterile or post-menopausal or using acceptable
             contraception and agree to use effective birth control regimen during the study
             period. Men must agree to use condoms during the study period. Women of child bearing
             potential must have a negative urine or serum pregnancy test.

         10. In the opinion of the Investigator, the subject is capable of understanding and
             complying with the protocol.

        Exclusion Criteria:

          1. Pregnant or nursing subjects and those who plan pregnancy in the period up to 6 months
             following index procedure.

          2. Cardiogenic shock (Killip class 4) or cardiac arrest

          3. History of prior myocardial infarction or pre-existing Q waves on ECG

          4. An elective surgical procedure is planned that would necessitate interruption of
             anti-platelet agents during the first six months post enrollment;

          5. Any contraindication to undergo MRI imaging. This will include any of the following
             exclusions:

               1. Cardiac pacemaker or implantable defibrillator;

               2. Non-MRI-compatible aneurysm clip;

               3. Neural stimulator (e.g., TENS-Unit);

               4. Any implanted or magnetically activated device (e.g., insulin pump);

               5. Any type of non-MRI-compatible metallic ear implant;

               6. Metal shavings in the orbits;

               7. Any metallic foreign body, shrapnel, or bullet in a location which the physician
                  feels would present a risk to the subject;

               8. Any history indicating contraindication to MRI, including claustrophobia or
                  allergy to gadolinium;

               9. Inability to follow breathhold instructions or to maintain a breathhold for &gt;15
                  seconds;

              10. Irregular cardiac rhythm not expected to resolve after treatment of the acute
                  cardiac condition (e.g., chronic atrial fibrillation)

              11. Known hypersensitivity or contraindication to gadolinium contrast.

          6. Subject has active bleeding or a history of bleeding diathesis or coagulopathy
             (including heparin induced thrombocytopenia), or refusal to receive blood transfusions
             if necessary;

          7. Subjects presenting with cardiogenic shock (SBP &lt;80 mmHg for &gt;30 minutes, or requiring
             IV pressors or emergency IABP for hypotension treatment) or cardiopulmonary
             resuscitation prior to randomization;

          8. History of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic
             stroke; stroke or transient ischemic attack within the past 6 months, or any permanent
             residual neurologic defect; known preceding cardiac ventricular arrhythmia

          9. Impaired renal function (eGFR of ≤30 ml/min/1.73m2, as estimated by the MDRD4v
             equation) or on dialysis.

         10. Impaired hepatic function (ALT &gt; 2x upper limit of normal, or a total bilirubin
             greater than 1.5 x upper limit of normal).

         11. Currently participating in or has participated in an investigational drug or medical
             device study within 30 days or 5 half-lives, whichever is longer, prior to enrollment
             into this study

         12. Have an active malignancy or history of solid, metastatic, or hematologic malignancy
             with the exception of basal or squamous cell carcinoma of the skin that has been
             removed

         13. History of positive human immunodeficiency virus (HIV) test

         14. History of rheumatoid arthritis

         15. History of proliferative retinopathy or laser surgery for retinopathy

         16. Subjects who require cytochrome P450 1A2 (CYP1A2) inhibitors, ciprofloxacin and/or
             fluvoxamine (Luvox®)

         17. Subject has other medical illness or known history of substance abuse (alcohol,
             cocaine, heroin etc.) that may cause non-compliance with the protocol, confound the
             data interpretation or is associated with a limited life expectancy of less than 6
             months,

         18. Any significant medical condition which in the Investigator's opinion may interfere
             with the subject's optimal participation in the study;

         19. Subject has a known hypersensitivity or allergy to stainless steel, nickel, cobalt
             chromium, nitinol, titanium or known hypersensitivity or allergy to contrast media
             (e.g. rash) that cannot effectively be controlled by premedication with steroids
             and/or diphenhydramine. Subjects with hypersensitivity or allergy to any of the
             components of the device (structural, drug or polymer components) and subjects with
             true prior anaphylaxis to contrast media should not be enrolled
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weizhong Cai</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417-1139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University Medical Center</name>
      <address>
        <city>New Haven</city>
        <state>New York</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2012</study_first_submitted>
  <study_first_submitted_qc>February 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2012</study_first_posted>
  <results_first_submitted>October 29, 2014</results_first_submitted>
  <results_first_submitted_qc>October 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2014</results_first_posted>
  <last_update_submitted>November 7, 2014</last_update_submitted>
  <last_update_submitted_qc>November 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatocyte growth factor mimetic</keyword>
  <keyword>hepatocyte growth factor(HGF)</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Acute ST Segment Elevation Myocardial Infarction (STEMI)</keyword>
  <keyword>Percutaneous Coronary Intervention (PCI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BB3, 4 Daily Doses</title>
          <description>BB3: Daily intravenous administration of 2 mg/kg BB3 for four (4) days ; 10 to 12 minutes; small molecule mimetic of hepatocyte growth factor</description>
        </group>
        <group group_id="P2">
          <title>Placebo; 4 Daily Doses</title>
          <description>Placebo: Normal saline; Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Complete Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BB3, 4 Daily Doses</title>
          <description>BB3: Daily intravenous administration of 2 mg/kg BB3 for four (4) days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Normal saline. Daily intravenous administration for four (4) days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="50" upper_limit="75"/>
                    <measurement group_id="B2" value="57.5" lower_limit="46" upper_limit="69"/>
                    <measurement group_id="B3" value="59" lower_limit="46" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Reduction in Infarct Size</title>
        <description>Evaluation of reduction in infarct size by MRI between the BB3 and placebo treatment groups at 6 months based on index of myocardial salvage</description>
        <time_frame>6 month</time_frame>
        <population>Five subjects were enrolled into the study; 3 subjects were randomized to BB3 and 2 subjects to placebo. Of the 3 subjects randomized to BB3, 1 completed study treatment; all three subjects discontinued the study prematurely. The two subjects randomized to placebo completed study treatment and neither discontinued the study prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>BB3, 4 Daily Doses</title>
            <description>BB3: Daily intravenous administration of 2 mg/kg BB3 for four (4) days</description>
          </group>
          <group group_id="O2">
            <title>Placebo, 4 Daily Doses</title>
            <description>Normal saline. Daily intravenous administration for four (4) days.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Reduction in Infarct Size</title>
          <description>Evaluation of reduction in infarct size by MRI between the BB3 and placebo treatment groups at 6 months based on index of myocardial salvage</description>
          <population>Five subjects were enrolled into the study; 3 subjects were randomized to BB3 and 2 subjects to placebo. Of the 3 subjects randomized to BB3, 1 completed study treatment; all three subjects discontinued the study prematurely. The two subjects randomized to placebo completed study treatment and neither discontinued the study prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of the Degree of Late Ventricular Remodeling</title>
        <description>Evaluation of the degree of late ventricular remodeling between the BB3 and placebo treatment groups at 6 months, as measured by increase in LV end-diastolic volume index (LVEDVI) from initial MR image (day 5±1) to late MR image (6 months).</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CK-MB and Troponin</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BNP Levels</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Symptoms and Clinical Signs of CHF</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LVEDVI, LVESVI and LV Ejection Fraction (EF) After MI Assessed by Cine MR (SSFP Imaging)</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LVEDVI, LVESVI and LVEF After MI Assessed by 2D and 3D Echocardiography</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Between Initial Semi-quantitative Regional Wall Motion Score (17 Segment Model) by Echocardiography</title>
        <time_frame>1 and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Regional Myocardial Radial, Circumferential and Longitudinal Strain</title>
        <time_frame>1 and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of MACE</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of New Onset CHF Through 6 Months</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospitalizations for CHF Through 6 Months</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Complete ST Segment Resolution 60 ± 30 Minutes After Last Angiogram</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of AE, SAEs</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of MACCE</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Ventricular Fibrillation or Other Life-threatening Arrhythmia</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline eCrCl</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptoms and Clinical Signs of CHF</title>
        <description>Symptoms and clinical signs of CHF measured by NYHA classification</description>
        <time_frame>6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BB3 Small Molecule Mimetic of Hepatocyte Growth Factor</title>
          <description>small molecule mimetic of hepatocyte growth factor/scatter factor
BB3: Daily intravenous administration of 2 mg/kg BB3 for four (4) days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Normal saline
Placebo: Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Five subjects were enrolled into the study; 3 subjects were randomized to BB3 and 2 subjects to placebo. All the 3 subjects randomized to BB3 discontinued the study prematurely. The 2 subjects randomized to placebo completed study treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Joesph Brennan</name_or_title>
      <organization>Yale University Medical Center</organization>
      <phone>(203) 483-8300</phone>
      <email>Brennan.Joesph@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

